Biotech Values

[Mufaso]

Biowatch's response to your post is on whetherVK2735 is a peptide is exceptional and very enlightening. (Thanks Biowatch!!) Thank you also for providing the patent link!

You also asked:

May I ask where you read that it is a peptide?

See Viking's corporate presentation slide 7 entitled "Novel Peptide-Based Dual Agonists". There VK2735 is listed as one of the novel peptide dual agonists VKTX tested preclinically so they are saying it is a peptide.

Also in the 3rd q CC there was this exchange regarding VK2735:

Annabel Samimy

Yes, I'm not worried about the non-competitiveness of the mechanism. I think the dual agonists are pretty strong. I'm just wondering if you had any reservations about getting a larger molecule into an oral formulation, if that is one of the reasons for your more cautious or conservative expectations.

Brian Lian

No, no. It's just generally the exposure levels from oral peptides are lower than sub-Q. So that would tend to lead to a lower level of efficacy long-term. And that's kind of what we've seen in other settings as well. But over 28 days, I think we're just looking for a signal of are the exposures there? Are we seeing some weight loss? And is the tolerability acceptable?

So Brian Lian called it an oral peptide while also providing some important color on expectations for the upcoming readout.